Breakthrough Brief is paused while we strengthen editorial review. Interest: info@medcelerator.com
medcelerator
Contact

Latest

Every verified treatment and trial we have published, newest first. Filter by country, access level, or patient stories.
All countriesUnited StatesCanadaUnited KingdomJapanChinaAustraliaSwitzerlandEuropean UnionNewestPatient StoriesFDA Approved ×
FDA ApprovedUnited StatesUnited KingdomEuropean Union

Once-Daily Pill for Adults with Untreated CLL or SLL

Jaypirca (pirtobrutinib) — once-daily pill for adults with previously untreated CLL or SLL and no known 17p deletion

US label section 1.3 added 10/2026; BRUIN CLL-313 NCT05023980

This is for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not been treated before and have no known 17p deletion.

FDA ApprovedUnited StatesEuropean Union

Pill for Teens and Adults with Severe Alopecia Areata

Olumiant (baricitinib) — once-daily pill for teens and adults with severe alopecia areata

US label expanded 09/2026 to ages 12+; EU SmPC already covers adolescents; BRAVE-AA-PEDS NCT05723198

This is for families and adults living with severe alopecia areata who are 12 years or older.

FDA ApprovedUnited StatesEuropean Union

Once-Weekly Basal Insulin Shot for Adults with Type 2 Diabetes

Onswik (insulin efsitora alfa-gobe) — once-weekly basal insulin for adults with type 2 diabetes

Onswik (insulin efsitora alfa) is a once-weekly long-acting insulin for adults with type 2 diabetes.

This is for adults with type 2 diabetes — and caregivers helping them — who may be candidates for a once-weekly basal insulin instead of a daily basal shot.

FDA ApprovedUnited StatesEuropean Union

First FDA-Approved Treatment for MCT8 Peripheral Thyrotoxicosis

Emcitate (tiratricol) — dispersible tablets for peripheral thyrotoxicosis in MCT8 deficiency

FDA approved Emcitate (tiratricol) tablets for oral suspension on 28 September 2026 — Novel Drug Approvals 2026 #45 — for treatment of peripheral…

This is for people living with MCT8 deficiency (Allan-Herndon-Dudley syndrome) — and the caregivers who help them — who need a realistic route to tiratricol.

FDA ApprovedUnited StatesUnited KingdomEuropean Union

First FDA-Approved Eye Form of Bevacizumab for Wet AMD

Lytenava (bevacizumab-vikg) — ophthalmic VEGF inhibitor injection for wet age-related macular degeneration

FDA approval on 24 July 2026 for Lytenava (bevacizumab-vikg) injection — an ophthalmic VEGF inhibitor for intravitreal use — for neovascular (wet) age-related…

This is for adults with wet age-related macular degeneration who may be candidates for labelled US Lytenava monthly eye injections — the first FDA-approved…

FDA ApprovedUnited StatesCanadaUnited KingdomEuropean Union

New Pill for Scarred-Lung Disease in Adults

Jascayd (nerandomilast) for IPF and PPF

The FDA, Europe, and the UK have labelled nerandomilast for adults with idiopathic pulmonary fibrosis and for adults with progressive pulmonary fibrosis.

Jascayd (nerandomilast) is approved in the United States, Europe and the United Kingdom.